Preoperative Serum Sex Hormone-Binding Globulin as a Predictive Marker for Extraprostatic Extension of Tumor in Patients with Clinically Localized Prostate Cancer

European Urology

Volumn 54, Issue 6, 2008, Pages 1324-1332

  Lee, Sang Eun ^a   Chung, Jae Seung ^a   Han, Byung Kyu ^a   Park, Chan Soo ^a   Moon, Ki Hyuk ^a   Byun, Seok Soo ^a   Choe, Gheeyoung ^a   Hong, Sung Kyu ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

Pathological stage; Prostate cancer; Prostatectomy; Sex hormone binding globulin

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; DIAGNOSTIC ACCURACY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIVARIATE ANALYSIS; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; ROC CURVE;

AGED; ANDROGENS; BIOLOGICAL MARKERS; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROSTATIC NEOPLASMS; SEX HORMONE-BINDING GLOBULIN;

EID: 55649084125     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.02.032     Document Type: Article

References (24)

1. Winters S.J., Brufsky A., Weissfeld J., Trump D.L., Dyky M.A., and Hadeed V. Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men. Metabolism 50 (2001) 1242-1247
2. Joseph D.R. Structure, function, and regulation of androgen-binding protein/sex hormone-binding globulin. Vitam Horm 49 (1994) 197-280
3. Vermeulen A., Kaufman J.M., and Giagulli V.A. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 81 (1996) 1821-1826
4. Grasso M., Buonaguidi A., Mondina R., Borsellino G., Lania C., Banfi G., et al. Plasma sex hormone binding globulin in patients with prostatic carcinoma. Cancer 66 (1990) 354-357
5. Hryb D.J., Nakhla A.M., Kahn S.M., St George J., Levy N.C., Romas N.A., et al. Sex hormone-binding globulin in the human prostate is locally synthesized and may act as an autocrine/paracrine effector. J Biol Chem 277 (2002) 26618-26622
6. WHO Expert Consultation. Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363 (2004) 157-163
7. Schatzl G., Madersbacher S., Thurridl T., et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47 (2001) 52-58
8. Schatzl G., Madersbacher S., Haitel A., et al. Association of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 169 (2003) 1312-1315
9. Yamamoto S., Yonese J., Kawakami S., et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 52 (2007) 696-701
10. Zagars G.K., Pollack A., and von Eschenbach A.C. Serum testosterone-a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology 49 (1997) 327-334
11. Fodstad P., Bjoro T., Torlakovic G., and Fossa S.D. No association of serum gonadal or pituitary hormones with prognostic parameters in stages T1 to T3 PN0M0 prostate cancer. J Urol 168 (2002) 1188-1192
12. Teloken C., Da Ros C.T., Caraver F., Weber F.A., Cavalheiro A.P., and Graziottin T.M. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 174 (2005) 2178-2180
13. Imamoto T., Suzuki H., Fukasawa S., et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 47 (2005) 308-312
14. Hoffman M.A., DeWolf W.C., and Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer?. J Urol 163 (2000) 824-827
15. San Francisco I.F., Regan M.M., Dewolf W.C., and Olumi A.F. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol 175 (2006) 1341-1345
16. Raivio T., Santti H., Schatzl G., et al. Reduced circulating androgen bioactivity in patients with prostate cancer. Prostate 55 (2003) 194-198
17. Haapiainen R., Rannikko S., Alfthan O., and Adlercreutz H. Pretreatment plasma levels of testosterone and sex hormone binding globulin binding capacity in relation to clinical staging and survival in prostatic cancer patients. Prostate 12 (1988) 325-332
18. Hryb D.J., Khan M.S., Romas N.A., and Rosner W. Solubilization and partial characterization of the sex hormone-binding globulin receptor from human prostate. J Biol Chem 264 (1989) 5378-5383
19. Ding V.D., Moller D.E., Feeney W.P., et al. Sex hormone-binding globulin mediates prostate androgen receptor action via a novel signaling pathway. Endocrinology 139 (1998) 213-218
20. Weigel N.L., and Zhang Y. Ligand-independent activation of steroid hormone receptors. J Mol Med 76 (1998) 469-479
21. Onat A., Hergenc G., Karabulut A., Albayrak S., Can G., and Kaya Z. Serum sex hormone-binding globulin, a determinant of cardiometabolic disorders independent of abdominal obesity and insulin resistance in elderly men and women. Metabolism 56 (2007) 1356-1362
22. Nielsen T.L., Hagen C., Wraae K., Brixen K., Petersen P.H., Haug E., et al. Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone-binding globulin, and luteinizing hormone in young men. J Clin Endocrinol Metab 92 (2007) 2696-2705
23. Mohr B.A., Bhasin S., Link C.L., O'Donnell A.B., and McKinlay J.B. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur J Endocrinol 155 (2006) 443-452
24. Kattan M.W. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 95 (2003) 634-635